VNRX: 3Q 2025 results reported; Revenues & EPS above our expectations; cost cutting very evident. At least seven major operational milestones have been achieved thus far in 2025.
AI Sentiment
Highly Positive
8/10
as of 12-02-2025 4:00pm EST
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HENDERSON |
| Market Cap: | 40.8M | IPO Year: | N/A |
| Target Price: | $3.17 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.29 - $0.94 | Next Earning Date: | 11-13-2025 |
| Revenue: | $1,472,007 | Revenue Growth: | 14.48% |
| Revenue Growth (this year): | 324.32% | Revenue Growth (next year): | 247.82% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
VNRX Breaking Stock News: Dive into VNRX Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
8/10
See how VNRX stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "VNRX VolitionRX Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.